These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides. Echigoya Y; Yokota T Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394 [TBL] [Abstract][Full Text] [Related]
30. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Takeshima Y; Yagi M; Wada H; Ishibashi K; Nishiyama A; Kakumoto M; Sakaeda T; Saura R; Okumura K; Matsuo M Pediatr Res; 2006 May; 59(5):690-4. PubMed ID: 16627883 [TBL] [Abstract][Full Text] [Related]
31. Contributions of Japanese patients to development of antisense therapy for DMD. Matsuo M; Takeshima Y; Nishio H Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594 [TBL] [Abstract][Full Text] [Related]
32. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy. Kendall GC; Mokhonova EI; Moran M; Sejbuk NE; Wang DW; Silva O; Wang RT; Martinez L; Lu QL; Damoiseaux R; Spencer MJ; Nelson SF; Miceli MC Sci Transl Med; 2012 Dec; 4(164):164ra160. PubMed ID: 23241744 [TBL] [Abstract][Full Text] [Related]
33. Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. Ousterout DG; Kabadi AM; Thakore PI; Perez-Pinera P; Brown MT; Majoros WH; Reddy TE; Gersbach CA Mol Ther; 2015 Mar; 23(3):523-32. PubMed ID: 25492562 [TBL] [Abstract][Full Text] [Related]
34. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy. Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660 [TBL] [Abstract][Full Text] [Related]
35. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Anthony K; Cirak S; Torelli S; Tasca G; Feng L; Arechavala-Gomeza V; Armaroli A; Guglieri M; Straathof CS; Verschuuren JJ; Aartsma-Rus A; Helderman-van den Enden P; Bushby K; Straub V; Sewry C; Ferlini A; Ricci E; Morgan JE; Muntoni F Brain; 2011 Dec; 134(Pt 12):3547-59. PubMed ID: 22102647 [TBL] [Abstract][Full Text] [Related]
36. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells. De Angelis FG; Sthandier O; Berarducci B; Toso S; Galluzzi G; Ricci E; Cossu G; Bozzoni I Proc Natl Acad Sci U S A; 2002 Jul; 99(14):9456-61. PubMed ID: 12077324 [TBL] [Abstract][Full Text] [Related]
37. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs. Maruyama R; Aoki Y; Takeda S; Yokota T Methods Mol Biol; 2018; 1828():365-379. PubMed ID: 30171554 [TBL] [Abstract][Full Text] [Related]
38. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy. Komaki H; Nagata T; Saito T; Masuda S; Takeshita E; Sasaki M; Tachimori H; Nakamura H; Aoki Y; Takeda S Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669851 [TBL] [Abstract][Full Text] [Related]
39. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Dunckley MG; Manoharan M; Villiet P; Eperon IC; Dickson G Hum Mol Genet; 1998 Jul; 7(7):1083-90. PubMed ID: 9618164 [TBL] [Abstract][Full Text] [Related]
40. Exon deletion patterns of the dystrophin gene in 82 Vietnamese Duchenne/Becker muscular dystrophy patients. Tran VK; Ta VT; Vu DC; Nguyen ST; Do HN; Ta MH; Tran TH; Matsuo M J Neurogenet; 2013 Dec; 27(4):170-5. PubMed ID: 24099565 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]